IMM-529 pre-clinical study indicates protection against C.diff infection and disease recurrence
IMM-529 pre-clinical study indicates protection against C.diff infection and disease recurrence
Click here to read more
IMM-529 pre-clinical study indicates protection against C.diff infection and disease recurrence
Fully protected by Incapsula
Join our social networks
Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies.
The company presently has three drug candidates in clinical development and several in early stage preclinical development. Immuron believes its therapeutic drug candidates have the potential to transform the existing treatment paradigms for moderate to severe Campylobacteriosis, recurrent Clostridiodes difficile (C.difficle) infections, Enterotoxigenic Escherichia coli (ETEC) infections, Shigellosis (Bacillary dysentery) and travelers’ diarrhea.